CSI Market
Sign In | Register

Nymox Pharmaceutical (NYMX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access NYMX Annual Cash Flow →
A period-by-period view of cash flow from Nymox Pharmaceutical to Dec 31 2023 helps clarify how Dec 31 2024's cash position has changed over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2024)
12 Months 		0 0 0 (Dec 31 2023)
Operating Activities
Income-4.49
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Adjustments For Sharebased Payments-
Issued Stock For Service Fee-
Amortization And Others-
Adjustments For Decrease Increase In Trade And Other Receivables-
Adjustments For Increase Decrease In Other Current Liabilities-
Adjustments For Decrease Increase In Inventories-
Employee Deposit Of Overpayment-
Adjustments For Increase Decrease In Trade Account Payable-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Accounts Payable0.00
Accrued Expense0.00
Adjustments For Increase Decrease In Deposits From Banks0.00
Prepaid Expense and Other Assets0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.01
Discontinued operations0.00
Net Cash flow from Operating Activities-2.60
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net2.60
Increase Decrease In Cash And Cash Equivalents-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities2.61
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-2.60
Total Cash Flow0.00
4 historic quarters locked

Sign in to unlock the full Nymox Pharmaceutical cash flow history.

Sign In Create Free Account

About Nymox Pharmaceutical Corp Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 20-F filings and normalized by CSIMarket.

Source & verification

  • Form: 20-F (Period: 20241231)
  • Filed with the SEC: June 3, 2025
  • Source: nymox_20f.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001640334-25-000972

Figures are derived from filed reports and may be restated. Historical data is subject to revision.